{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:03:23Z","timestamp":1793153003987,"version":"4.5.0"},"reference-count":116,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000\u00a0(CAD)\u00a0per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold is hypothesized to have a higher impact on the time to access these drugs in Canada. We studied the impact of price reductions on time to engagement and negotiation with the pan-Canadian Pharmaceutical Alliance for oncology drugs reviewed by CADTH between January 2020 and December 2022. Overall, 103 assessments reported data on price reductions recommended by CADTH to meet the cost\u2013effectiveness threshold for reimbursement. Of these assessments, 57% (59\/103) recommendations included a price reduction of greater than 70% off the list price. Eight percent (8\/103) were not cost-effective even at a 100% price reduction. Of the 47 assessments that had a clear benefit, in 21 (45%) CADTH recommended a price reduction of at least 70%. The median time to price negotiation (not including time to engagement) for assessments that received at least 70% vs &gt;70% price reduction was 2.6\u00a0vs 4.8\u00a0months. This study showed that there is a divergence between drug sponsor's incremental cost\u2013effectiveness ratio (ICER) and CADTH revised ICER leading to a price reduction to meet the $50,000\/QALY threshold. For the submissions with clear clinical benefit the median length of engagement (2.5 vs 3.3\u00a0months) and median length of negotiation (3.1 vs 3.6\u00a0months) were slightly shorter compared with the submissions where uncertainties were noted in the clinical benefit according to CADTH. This study shows that using a $50,000 per QALY threshold for oncology products potentially impacts timely access to life saving medications.<\/jats:p>","DOI":"10.57264\/cer-2023-0178","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T12:55:50Z","timestamp":1712148950000},"source":"Crossref","is-referenced-by-count":23,"title":["The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-2119","authenticated-orcid":false,"given":"Chakrapani","family":"Balijepalli","sequence":"first","affiliation":[{"name":"Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-6499","authenticated-orcid":false,"given":"Lakshmi","family":"Gullapalli","sequence":"additional","affiliation":[{"name":"Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Joshy","sequence":"additional","affiliation":[{"name":"Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-4890","authenticated-orcid":false,"given":"Nigel SB","family":"Rawson","sequence":"additional","affiliation":[{"name":"Canadian Health Policy Institute, Toronto, ON, Canada"},{"name":"Macdonald-Laurier Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_7_3_2","volume-title":"Canadian Cancer Statistics 2021","author":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society Statistics Canada and the Public Health Agency of Canada","year":"2021","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Canadian Cancer Society, Toronto, Canada (2021). http:\/\/www.cancer.ca\/Canadian-Cancer-Statistics-2021-EN"},{"issue":"4","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/curroncol29040223","article-title":"The economic burden of cancer in Canada from a societal perspective","volume":"29","author":"Garaszczuk R","year":"2022","unstructured":"Garaszczuk R, Yong JHE, Sun Z, de Oliveira C. The economic burden of cancer in Canada from a societal perspective. Curr. Oncol. 29(4), 2735\u20132748 (2022).","journal-title":"Curr. Oncol."},{"issue":"1","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.24095\/hpcdp.35.S1.02","article-title":"Cancer incidence in Canada: trends and projections (1983\u20132032)","volume":"35","author":"Xie L","year":"2015","unstructured":"Xie L, Semenciw R, Mery L. Cancer incidence in Canada: trends and projections (1983\u20132032). Health Promot. Chronic Dis. Prev. Can. 35(Suppl. 1), 2\u2013186 (2015).","journal-title":"Health Promot. Chronic Dis. Prev. Can."},{"key":"e_1_3_7_7_2","volume-title":"Canadian Cancer Statistics: a 2022 special report on cancer prevalence","author":"Canadian Cancer Statistics Advisory in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada","year":"2022","unstructured":"Canadian Cancer Statistics Advisory in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics: a 2022 special report on cancer prevalence. Canadian Cancer Society, Toronto, Canada (2022). https:\/\/cancer.ca\/en\/cancer-information\/resources\/publications\/canadian-cancer-statistics-a-2022-special-report-on-cancer-prevalence"},{"issue":"1","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1634\/theoncologist.2019-0314","article-title":"Potential life-years lost: the impact of the cancer drug regulatory and funding process in Canada","volume":"25","author":"Gotfrit J","year":"2020","unstructured":"Gotfrit J, Shin JJW, Mallick R, Stewart DJ, Wheatley-Price P. Potential life-years lost: the impact of the cancer drug regulatory and funding process in Canada. Oncologist 25(1), e130\u2013e137 (2020).","journal-title":"Oncologist"},{"key":"e_1_3_7_9_2","volume-title":"Has pCODR improved access to oncology drugs? Timeliness and provincial acceptance of pan-Canadian Oncology Drug Review recommendations","author":"Rawson NSB","year":"2014","unstructured":"Rawson NSB. Has pCODR improved access to oncology drugs? Timeliness and provincial acceptance of pan-Canadian Oncology Drug Review recommendations. Fraser Institute, Vancouver (2014). https:\/\/www.fraserinstitute.org\/sites\/default\/files\/has-pCODR-improved-access-to-oncology-drugs-rev.pdf"},{"key":"e_1_3_7_10_2","unstructured":"Health Canada. (2024). https:\/\/www.canada.ca\/en\/health-canada\/news\/2023\/12\/the-government-of-canada-announces-the-creation-of-the-canadian-drug-agency\u2014helping-make-canadas-drug-system-more-sustainable-and-better-prepared.html"},{"issue":"3","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/curroncol29030127","article-title":"Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations","volume":"29","author":"Binder L","year":"2022","unstructured":"Binder L, Ghadban M, Sit C, Barnard K. Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations. Curr. Oncol. 29(3), 1514\u20131526 (2022).","journal-title":"Curr. Oncol."},{"issue":"3","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41669-021-00311-5","article-title":"Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries","volume":"6","author":"Fontrier AM","year":"2022","unstructured":"Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. Pharmacoecon. Open 6(3), 315\u2013328 (2022).","journal-title":"Pharmacoecon. Open"},{"issue":"8","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11588250-000000000-00000","article-title":"Using QALYs in cancer: a review of the methodological limitations","volume":"29","author":"Garau M","year":"2011","unstructured":"Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics 29(8), 673\u2013685 (2011).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_7_14_2","unstructured":"CADTH Pembrolizumab (Keytruda) SNSCLC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10176PembrolizumabSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_03Jan2020_final.pdf"},{"key":"e_1_3_7_15_2","unstructured":"CADTH Trastuzumab Emtansine (Kadcyla) EBC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10182TrastuzumabEmtansineEBC_fnEGR_NOREDACT-ABBREV_EarlyConv_22Jan2020_final.pdf"},{"key":"e_1_3_7_16_2","unstructured":"CADTH Pembrolizumab (Keytruda) RCC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10185PembrolizumabRCC_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf"},{"key":"e_1_3_7_17_2","unstructured":"CADTH Cabozantinib (Cabometyx) HCC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf"},{"key":"e_1_3_7_18_2","unstructured":"CADTH Cemiplimab (Libtayo) CSCC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10187CemiplimabCSCC_fnEGR_REDACT-ABBREV_EarlyConv_22Jan2020_final.pdf"},{"key":"e_1_3_7_19_2","unstructured":"CADTH Daratumumab (Darzalex) + Rd MM__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10189DaratumumabNDMM_fnEGR_NOREDACTABBREV_Post05Mar2020_final.pdf"},{"key":"e_1_3_7_20_2","unstructured":"CADTH Gemtuzumab Ozogamicin (Mylotarg) AML__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10190GemtuzumabOzogamicinAML_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf"},{"key":"e_1_3_7_21_2","unstructured":"CADTH Ribociclib (Kisqali) Advanced or Metastatic BC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10194RibociclibMBC_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf"},{"key":"e_1_3_7_22_2","unstructured":"CADTH Ribociclib (Kisqali) + Fulvestrant Advanced or Metastatic BC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf"},{"key":"e_1_3_7_23_2","unstructured":"CADTH Darolutamide (Nubeqa) nmCRPC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10196DarolutamidenmCRPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf"},{"key":"e_1_3_7_24_2","unstructured":"CADTH Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10197TrifluridineTipiracilGC_inEGR_NOREDACT-ABBREV_EC24Mar2020_final.pdf"},{"key":"e_1_3_7_25_2","unstructured":"CADTH Brentuximab Vedotin (Adcetris) PTCL__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10199BrentuximabVedotinPTCL_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf"},{"key":"e_1_3_7_26_2","unstructured":"CADTH Apalutamide (Erleada) mCSPC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10200ApalutamidemCSPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf"},{"key":"e_1_3_7_27_2","unstructured":"CADTH Gilteritinib (Xospata) AML__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10202GilteritinibAML_fnEGR_REDACT-ABBREV_EarlyConv20May2020_final.pdf"},{"key":"e_1_3_7_28_2","unstructured":"CADTH Niraparib (Zejula) OC __ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10203NiraparibOC_fnEGR_REDACTABBREV_Post03Sep2020_final.pdf"},{"key":"e_1_3_7_29_2","unstructured":"CADTH Blinatumomab (Blincyto) MRD+ BCP ALL__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10204BlinatumomabMRD%2BBCPALL_fnEGR_NOREDACTABBREV_Post29Oct2020_final.pdf"},{"key":"e_1_3_7_30_2","unstructured":"CADTH Entrectinib (Rozlytrek) ROS1-positive NSCLC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10206EntrectinibROS1NSCLC_fnEGR_NOREDACT-ABBREV_EC27Jan2021_final.pdf"},{"key":"e_1_3_7_31_2","unstructured":"CADTH Enzalutamide (Xtandi) mCSPC__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10209EnzalutamidemCSPC_fnEGR_REDACT-ABBREV_Post_23Sep2020_final.pdf"},{"key":"e_1_3_7_32_2","unstructured":"CADTH Acalabrutinib (Calquence) CLL(previously untreated)__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10210AcalabrutinibCLL%28previously%20untreated%29_fnEGR_REDACTABBREV_Post08Jan2021_final.pdf"},{"key":"e_1_3_7_33_2","unstructured":"CADTH Acalabrutinib (Calquence) CLL__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10211AcalabrutinibCLL_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf"},{"key":"e_1_3_7_34_2","unstructured":"CADTH Venetoclax (Venclexta) Obinutuzumab CLL__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10212VenetoclaxObinutuzumabCLL_fnEGR_NOREDACTABBREV_EC_Post17Nov2020_final.pdf"},{"key":"e_1_3_7_35_2","unstructured":"CADTH Brentuximab Vedotin (Adcetris) pcALCL MF__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10213BrentuximabVedotinpcALCLMF_fnEGR_NOREDACTABBREV_03Dec2020_final.pdf"},{"key":"e_1_3_7_36_2","unstructured":"CADTH Brentuximab Vedotin (Adcetris) HL AVD__ pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10214BrentuximabVedotinHLAVD_fnEGR_NOREDACT-ABBREV_03Dec2020_final.pdf"},{"key":"e_1_3_7_37_2","unstructured":"CADTH Pembrolizumab (Keytruda) HNSCC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10216PembrolizumabHNSCC_fnEGR_REDACTABBREV_EC22Dec2020_final.pdf"},{"key":"e_1_3_7_38_2","unstructured":"CADTH Atezolizumab (Tecentriq) Bevacizumab HCC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10217AtezolizumabBevacizumabHCC_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf"},{"key":"e_1_3_7_39_2","unstructured":"CADTH Nivolumab (Opdivo) Ipilimumab NSCLC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10218Nivolumab-IpilimumabNSCLC_fnEGR_NOREDACT-ABBREV_Post04Mar2021_final.pdf"},{"key":"e_1_3_7_40_2","unstructured":"CADTH Isatuximab (Sarclisa) MM__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf"},{"key":"e_1_3_7_41_2","unstructured":"CADTH Larotrectinib (Vitrakvi) NTRK+ Solid Tumors__ pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0221-Vitrakvi-combined-report-meta.pdf"},{"key":"e_1_3_7_42_2","unstructured":"CADTH Dinutuximab (Unituxin) neuroblastoma__pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/PC0222-combined%20report%20for%20posting.pdf"},{"key":"e_1_3_7_43_2","unstructured":"CADTH Olaparib (Lynparza) mCRPC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf"},{"key":"e_1_3_7_44_2","unstructured":"CADTH Niraparib (Zejula) first line OC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf"},{"key":"e_1_3_7_45_2","unstructured":"CADTH Avelumab (Bavencio) UC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10225AvelumabUC_fnEGR_REDACT-ABBREV_EC23Mar2021_final.pdf"},{"key":"e_1_3_7_46_2","unstructured":"CADTH Dabrafenib and Trametinib NSCLC BRAF V600__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10226Dabrafenib-TrametinibNSCLC_fnEGR_REDACT-ABBREV_Post28May2021_final.pdf"},{"key":"e_1_3_7_47_2","unstructured":"CADTH Polatuzumab Vedotin (Polivy) DLBCL __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf"},{"key":"e_1_3_7_48_2","unstructured":"CADTH Nivolumab-ipilimumab MPM__pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0229-Opdivo-Yervoy-combined.pdf"},{"key":"e_1_3_7_49_2","unstructured":"CADTH Brigatinib (Alunbrig) ALK + NSCLC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10230BrigatinibALK%2BNSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf"},{"key":"e_1_3_7_50_2","unstructured":"CADTH Encorafenib and binimetinib MM__pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0232-combined.pdf"},{"key":"e_1_3_7_51_2","unstructured":"CADTH Encorafenib (Braftovi) + cetuximab mCRC BRAF V600E__pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/PC0233-braftovi-combined-revised.pdf"},{"key":"e_1_3_7_52_2","unstructured":"CADTH Durvalumab (Imfinzi) ES-SCLC __pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0234-combined-final.pdf"},{"key":"e_1_3_7_53_2","doi-asserted-by":"crossref","unstructured":"CADTH Pembrolizumab (Keytruda) CRC SCLC __pCODR Final Clinical and Pharmacoeconomics combined report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0235-Keytruda-Combined.pdf","DOI":"10.51731\/cjht.2022.448"},{"key":"e_1_3_7_54_2","unstructured":"CADTH Pembrolizumab (Keytruda) cHL __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0236%20Keytruda-combined-report.pdf"},{"key":"e_1_3_7_55_2","unstructured":"CADTH Daunorubicin and Cytarabine Liposome (Vyxeos) t-AML or AML-MRC __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0237-combined-report-final.pdf"},{"key":"e_1_3_7_56_2","unstructured":"CADTH Venetoclax (Venclexta) AML __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0238-combined-report-FINAL.pdf"},{"key":"e_1_3_7_57_2","unstructured":"CADTH Tucatinib (Tukysa) mBC __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0243-Tukysa-combined.pdf"},{"key":"e_1_3_7_58_2","unstructured":"CADTH Azacitidine (Onureg) AML __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0245-Onureg-combined-Final.pdf"},{"key":"e_1_3_7_59_2","doi-asserted-by":"crossref","unstructured":"CADTH Zanubrutinib (Brukinsa) WM__pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0248-Brukinsa.pdf","DOI":"10.51731\/cjht.2022.453"},{"key":"e_1_3_7_60_2","doi-asserted-by":"crossref","unstructured":"CADTH Pembrolizumab (Keytruda) Esophageal carcinoma __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0250CL-Keytruda.pdf","DOI":"10.51731\/cjht.2022.448"},{"key":"e_1_3_7_61_2","unstructured":"CADTH Brexucabtagene Autoleucel (Tecartus) MCL carcinoma __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PG0219-tecartus-combined-report-meta.pdf"},{"key":"e_1_3_7_62_2","unstructured":"CADTH Atezolizumab (Tecentriq) -Bevacizumab NSQ-NSCLC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10155AtezolizumabBevacizumabNSQ-NSCLC_fnEGR_REDACT-ABBREV_Post03Jul2020_final.pdf"},{"key":"e_1_3_7_63_2","unstructured":"CADTH Atezolizumab (Tecentriq) SCLC__pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10156AtezolizumabSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf"},{"key":"e_1_3_7_64_2","unstructured":"CADTH Lorlatinib (Lorbrena) NSCLC __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10183LorlatinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf"},{"key":"e_1_3_7_65_2","unstructured":"CADTH Midostaurin (Rydapt) ASM __pCODR Final Economic Guidance Report. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10193MidostaurinSM_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf"},{"key":"e_1_3_7_66_2","unstructured":"CADTH Glasdegib (Daurismo) AML __pCODR Final Economic Guidance Report. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10207GlasdegibAML_fnEGR_NOREDACT-ABBREV_Post08Jan2021_final.pdf (Accessed: 25 February 2022)."},{"key":"e_1_3_7_67_2","unstructured":"CADTH Sonidegib (Odomzo) BCC __pCODR Final Economic Guidance Report. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf (Accessed: 25 February 2022)."},{"key":"e_1_3_7_68_2","unstructured":"CADTH Venetoclax (Venclexta) AML __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0239-combined-report.pdf"},{"key":"e_1_3_7_69_2","unstructured":"CADTH Idecabtagene Vicleucel (Abecma) MM AML __pCODR Final Clinical and Pharmacoeconomics combined. (Accessed 25 February 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PG0240-Abecma.pdf"},{"key":"e_1_3_7_70_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pertuzumab (Perjeta). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0241%20Perjeta%20-%20Final%20CADTH%20Rec_Final.pdf"},{"key":"e_1_3_7_71_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Mogamulizumab (Poteligeo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0244REC-Poteligeo.pdf","DOI":"10.51731\/cjht.2022.432"},{"key":"e_1_3_7_72_2","unstructured":"CADTH CADTH Reimbursement Review Osimertinib (Tagrisso). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0246-Tagrisso-rec%20Final.pdf"},{"key":"e_1_3_7_73_2","unstructured":"CADTH CADTH Reimbursement Recommendation Alpelisib (Piqray). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0247%20Piqray%20-%20Final%20CADTH%20Rec-meta.pdf"},{"key":"e_1_3_7_74_2","unstructured":"CADTH CADTH Reimbursement Recommendation Lorlatinib (Lorbrena). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0249%20Lorbrena%20-%20CADTH%20Final%20Rec.pdf"},{"key":"e_1_3_7_75_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Enfortumab Vedotin (Padcev). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0251REC-Padcev%20Final-meta.pdf","DOI":"10.51731\/cjht.2022.343"},{"key":"e_1_3_7_76_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pemigatinib (Pemazyre). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0252%20Pemazyre%20-%20CADTH%20Final%20Rec.pdf"},{"key":"e_1_3_7_77_2","unstructured":"CADTH CADTH Reimbursement Recommendation Nivolumab (Opdivo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0253%20Opdivo%20-%20CADTH%20Final%20Rec%20Final.pdf"},{"key":"e_1_3_7_78_2","unstructured":"CADTH CADTH Reimbursement Recommendation Sacituzumab Govitecan (Trodelvy). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0254%20Trodelvy%20-%20CADTH%20Final%20Rec-meta.pdf"},{"key":"e_1_3_7_79_2","unstructured":"CADTH CADTH Reimbursement Recommendation Isatuximab (Sarclisa). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0256%20Sarclisa%20-%20CADTH%20Final%20Rec%20revised.pdf"},{"key":"e_1_3_7_80_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Nivolumab (Opdivo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0259%20Opdivo%20-%20Final%20CADTH%20Rec.pdf","DOI":"10.51731\/cjht.2022.470"},{"key":"e_1_3_7_81_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Cemiplimab (Libtayo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0260REC-Libtayo_Final.pdf","DOI":"10.51731\/cjht.2022.433"},{"key":"e_1_3_7_82_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Selpercatinib (Retevmo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0261%20Retevmo%20-%20CADTH%20Final%20Rec-meta.pdf","DOI":"10.51731\/cjht.2022.469"},{"key":"e_1_3_7_83_2","unstructured":"CADTH CADTH Reimbursement Recommendation Cemiplimab (Libtayo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0262%20Libtayo%20NSCLC%20%20\u2013%20CADTH%20Final%20Rec.pdf"},{"key":"e_1_3_7_84_2","unstructured":"CADTH CADTH Reimbursement Recommendation Ripretinib (Qinlock). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0265%20Qinlock%20-%20Confidential%20Final%20CADTH%20Rec-meta.pdf"},{"key":"e_1_3_7_85_2","unstructured":"CADTH CADTH Reimbursement Recommendation Zanubrutinib (Brukinsa). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0267%20Brukinsa%20MCL%20-%20Final%20CADTH%20Recommendation%20Final.pdf"},{"key":"e_1_3_7_86_2","unstructured":"CADTH CADTH Reimbursement Recommendation Lenvatinib (Lenvima) in Combination With Pembrolizumab (Keytruda). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0268%20Lenvima%20and%20Keytruda%20-%20Final%20CADTH%20Rec_KT-meta.pdf"},{"key":"e_1_3_7_87_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Selpercatinib (Retevmo). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0274%20Retevmo%20DTC%20-%20CADTH%20Final.pdf","DOI":"10.51731\/cjht.2022.469"},{"key":"e_1_3_7_88_2","unstructured":"CADTH CADTH Reimbursement Recommendation Asciminib (Scemblix). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0275%20Scemblix%20-%20CADTH%20Final%20Rec.pdf"},{"key":"e_1_3_7_89_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Selinexor (Xpovio). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0276%20Xpovio%20-%20Final%20CADTH%20Recommendation_KT_KAS_KT_GP-meta.pdf","DOI":"10.51731\/cjht.2022.467"},{"key":"e_1_3_7_90_2","doi-asserted-by":"crossref","unstructured":"CADTH CADTH Reimbursement Recommendation Lisocabtagene Maraleucel (Breyanzi). (Accessed 10 November 2022). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PG0258%20Breyanzi%20-%20Final%20CADTH%20Rec-Final.pdf","DOI":"10.51731\/cjht.2022.461"},{"key":"e_1_3_7_91_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pembrolizumab (Keytruda). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0292%20Keytruda%20Cervical%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)_Final.pdf"},{"key":"e_1_3_7_92_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pembrolizumab (Keytruda). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0286%20Keytruda%20Melanoma%20-%20CADTH%20Final%20Rec%20Revised%20Jan.%2031.pdf"},{"key":"e_1_3_7_93_2","unstructured":"CADTH CADTH Reimbursement Recommendation Entrectinib (Rozlytrek). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0278%20Rozlytrek%20-%20CADTH%20Final%20Recommendation%20for%20Posting.pdf"},{"key":"e_1_3_7_94_2","unstructured":"CADTH CADTH Reimbursement Recommendation Cabozantinib (Cabometyx). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0287%20Cabometyx%20-%20CADTH%20Final%20Recommendation%20for%20formatting-meta.pdf"},{"key":"e_1_3_7_95_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pralsetinib (Gavreto). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0283%20Gavreto%20-%20CADTH%20Final%20Recommendation%20Final.pdf"},{"key":"e_1_3_7_96_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pembrolizumab (Keytruda). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0273%20Keytruda%20RCC%20-%20CADTH%20Final%20Recommendation_Final.pdf"},{"key":"e_1_3_7_97_2","unstructured":"CADTH CADTH Reimbursement Recommendation Tafasitamab (Minjuvi). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0266%20Minjuvi%20-%20CADTH%20Final%20Recommendation-Final.pdf"},{"key":"e_1_3_7_98_2","unstructured":"CADTH CADTH Reimbursement Recommendation Abemaciclib (Verzenio). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0282%20Verzenio%20-%20CADTH%20Final%20Recommendation%20(With%20Redactions)_Final.pdf"},{"key":"e_1_3_7_99_2","unstructured":"CADTH CADTH Reimbursement Recommendation Trastuzumab Deruxtecan (Enhertu). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0285%20Enhertu%20-%20Confidential%20Final%20CADTH%20Recommendation-KH%20-%20Validated-meta.pdf"},{"key":"e_1_3_7_100_2","unstructured":"CADTH CADTH Reimbursement Recommendation Lutetium (177Lu) Oxodotreotide (Lutathera). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0284%20Lutathera%20-CADTH%20Final%20Recommendation%20Final.pdf"},{"key":"e_1_3_7_101_2","unstructured":"CADTH CADTH Reimbursement Recommendation Nivolumab (Opdivo). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0272%20Opdivo%20UC%20-%20CADTH%20Final%20Recommendation%20Final.pdf"},{"key":"e_1_3_7_102_2","unstructured":"CADTH CADTH Reimbursement Recommendation Selpercatinib (Retevmo). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0264%20Retevmo%20MTC%20-%20Final%20CADTH%20Recommendation%20for%20Posting%20Final.pdf"},{"key":"e_1_3_7_103_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pembrolizumab (Keytruda) in Combination With Lenvatinib (Lenvima). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0288%20Keytruda%20and%20Lenvima%20-%20Final%20CADTH%20Recommendation.pdf"},{"key":"e_1_3_7_104_2","unstructured":"CADTH CADTH Reimbursement Recommendation Atezolizumab (Tecentriq). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0269%20Tecentriq%20for%20NSCLC%20-%20CADTH%20Final%20Recommendation-Final-meta.pdf"},{"key":"e_1_3_7_105_2","unstructured":"CADTH CADTH Reimbursement Recommendation Atezolizumab (Tecentriq). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0277%20Tecentriq%20SCLC%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20Final.pdf"},{"key":"e_1_3_7_106_2","unstructured":"CADTH CADTH Reimbursement Recommendation Pembrolizumab (Keytruda). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0279%20Keytruda%20TNBC%20-%20Final%20CADTH%20Recommendation%20Final.pdf"},{"key":"e_1_3_7_107_2","unstructured":"CADTH CADTH Reimbursement Recommendation Dostarlimab (Jemperli). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0263%20Jemperli%20-%20CADTH%20Final%20Recommendation_JH_SC-meta.pdf"},{"key":"e_1_3_7_108_2","unstructured":"CADTH CADTH Reimbursement Recommendation Tepotinib (Tepmetko). (Accessed 24 July 2023). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0255%20Tepmetko%20-%20CADTH%20Final%20Recommendation%20Final.pdf"},{"issue":"7","key":"e_1_3_7_109_2","doi-asserted-by":"crossref","first-page":"PA488","DOI":"10.1016\/j.jval.2016.09.821","article-title":"CADTH's $50,000 cost\u2013effectiveness threshold: fact or fiction","volume":"19","author":"Griffiths EA","year":"2016","unstructured":"Griffiths EA, Vadlamudi NK. CADTH's $50,000 cost\u2013effectiveness threshold: fact or fiction. Value Health 19(7), PA488\u2013A489 (2016).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_7_110_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12913-023-09095-2","article-title":"Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries","volume":"23","author":"Mills M","year":"2023","unstructured":"Mills M, Michaeli D, Miracolo A, Kanavos P. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Serv. Res. 23(1), 150 (2023).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_7_111_2","article-title":"Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy","author":"Michaeli DT","year":"2023","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur. J. Health Econ. doi:10.1007\/s10198-023-01639-x (2023) (Epub ahead of print).","journal-title":"Eur. J. Health Econ."},{"key":"e_1_3_7_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00535"},{"key":"e_1_3_7_113_2","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual (2022). (Accessed 6 October 2023). https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"issue":"9","key":"e_1_3_7_114_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40273-019-00810-8","article-title":"Severity-adjusted probability of being cost-effective","volume":"37","author":"Versteegh MM","year":"2019","unstructured":"Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WBF. Severity-adjusted probability of being cost-effective. Pharmacoeconomics 37(9), 1155\u20131163 (2019).","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"e_1_3_7_115_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.healthpol.2016.01.012","article-title":"A new proposal for priority setting in Norway: open and fair","volume":"120","author":"Ottersen T","year":"2016","unstructured":"Ottersen T, Forde R, Kakad M A new proposal for priority setting in Norway: open and fair. Health Policy 120(3), 246\u2013251 (2016).","journal-title":"Health Policy"},{"key":"e_1_3_7_116_2","unstructured":"Innovative Medicines Canada. (Accessed 24 July 2023). https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2023\/04\/6328_IMC_ME_IAA_Report_v6.pdf"},{"issue":"1","key":"e_1_3_7_117_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","article-title":"Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition","volume":"42","author":"Michaeli DT","year":"2024","unstructured":"Michaeli DT, Michaeli T. Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics 42(1), 117\u2013131 (2024).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_7_118_2","doi-asserted-by":"crossref","first-page":"e073242","DOI":"10.1136\/bmj-2022-073242","article-title":"FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis","volume":"381","author":"Michaeli T","year":"2023","unstructured":"Michaeli T, J\u00fcrges H, Michaeli DT. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ 381, e073242 (2023).","journal-title":"BMJ"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:19:36Z","timestamp":1713788376000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.57264\/cer-2023-0178"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0178","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"article-number":"e230178"}}